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A B S T R A C T
Objective: The aim of the present work was to test the concept of the heterologous prime-boost strategy
combining an infective dengue virus with a recombinant chimeric protein carrying domain III of the
envelope protein.
Methods: Two studies in monkeys, combining recombinant protein PD5 (domain III of the envelope
protein fromdengue-2 virus, fused to the protein carrier P64k) and the infective dengue virus in the same
immunization schedules were carried out. Humoral and cell-mediated immunity were evaluated.
Results: In the ﬁrst study, monkeys received four doses of the protein PD5 and were subsequently
infected with one dose of dengue virus. Antibody response measured after virus inoculation was
signiﬁcantly higher compared to that in non-primed monkeys and comparable to that elicited after two
doses of infective virus. In a second study, monkeys were infected with one dose of the virus and
subsequently boosted with one dose of the recombinant protein, reaching high levels of neutralizing
antibodies, which were still detectable 14 months after the last immunization. In addition, the cellular
immune response was also recalled.
Conclusions: The results obtained in the present work support the approach of heterologous prime-
boosting, in either order prime or boost, combining the chimeric protein PD5 (formulated in alum-CPS-A)
and an infective dengue virus. The latter could potentially be replaced by an attenuated vaccine candidate.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Dengue epidemics caused by the four dengue virus serotypes
DEN-1 to DEN-4 are a major problem in most tropical and
subtropical regions. According to estimates, asmany as 100million
dengue infections occur every year worldwide.1,2 The incidence of
dengue fever and dengue hemorrhagic fever is rising and there is
currently no vaccine available to prevent the disease.
Live attenuated viruses are the most advanced vaccine
candidates against the infection.3–5 Such vaccines have been
immunogenic in human clinical trials mostly due to their
replicative capacity. However, and due to this same feature,
reactogenicity in variable degrees has been reported in different
studies.5–7 In addition, two or three doses have been required to
induce a balanced tetravalent immune response.4,5,7* Corresponding author. Tel.: +53 7 271 6022; fax: +53 7 271 4764.
E-mail address: iris.valdes@cigb.edu.cu (I. Valde´s).
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doi:10.1016/j.ijid.2009.06.017As an alternative, to avoid the aforementioned disadvantages,
the subunit vaccine strategy has been one of the goals to which the
efforts of different groups have been directed.8–18 Speciﬁcally, our
group has developed different constructs based on the protein
P64k of Neisseria meningitidis and domain III of the envelope (E)
protein from dengue virus. The safety and the carrier capacity of
the protein P64k have previously been proved in humans with
successful results.19,20 The recombinant fusion molecules of
serotypes 1–4 expressed in Escherichia coli have been puriﬁed21
and successfully evaluated in mice.17,22,23 In addition, DEN-1 and
DEN-2 constructs, adjuvanted in Freund’s adjuvant, were found to
be immunogenic and conferred protection in monkeys against
challenge with the homologous infective virus.14,16 Moreover,
when formulations suitable for human use were evaluated, only
the combination with the serogroup A capsular polysaccharide
(CPS-A) from N. meningitidis adsorbed in aluminum hydroxide,
exhibited partial protection in monkeys.18
While safety is one of the crucial attributes of vaccine
candidates based on recombinant proteins, the induction of ases. Published by Elsevier Ltd. All rights reserved.
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human use has yet to be proved.
Based on the advantages and disadvantages of the subunit and
the attenuated virus candidates, the presentwork had testing of the
concept of the prime-boost strategy, combining the two types of
candidates, as its main goal. We selected a formulation containing
the recombinant chimericproteinPD5 (domain III, aminoacids286–
426of the E protein fromDEN-2 virus, fused to the C-terminus of the
carrier protein P64k), suitable for human use, which was able to
partially protect monkeys against viral challenge.18 In turn, a single
dose of infective DEN-2 virus was considered as a model of an
attenuated viral strain. Some of the results of this work are an
extension of a previous study on the immunological evaluation of
two formulations of PD5 in monkeys.18 The kinetics of antibody
response in vaccinated monkeys after challenge was measured and
compared with that elicited in monkeys receiving one or two doses
of the infective virus. Furthermore, a second studywas conducted in
monkeys to determine the boosting capacity of one formulation of
PD5 after one dose of infective virus.
2. Materials and methods
2.1. Animals
Healthy adult green monkeys (Chlorocebus (formerly Cerco-
pithecus) aethiops sabaeus) were obtained from CENPALAB
(Havana, Cuba). All animals were screened for previous exposure
to dengue virus by ELISA and plaque reduction neutralization test
(PRNT), and to P64k protein by ELISA. Animals were considered
naive with respect to both antigens when antigen-speciﬁc
antibodies were undetectable by ELISA (titer <1:100) and PRNT
(titer <1:10). Monkeys were maintained in accordance with the
Cuban guidelines for the care and use of laboratory animals.
2.2. Viruses
Preparation from suckling mouse brain infected with dengue-2
virus (strain NewGuinea C)was used as sucrose–acetone antigen24
for immunoassay tests. A similar preparation obtained from brain
of non-inoculatedmicewas used as negative control. For the PRNT,
cell culture supernatant harvested from Vero cells infected with
DEN-2 virus, strain SB8553 (kindly provided by Dr M.J. Cardosa,
University Sarawak, Malaysia) was used. A viral stock for the
challenge study was prepared with the DEN-2 strain SB8553 in
Vero cells using fresh supplemented RPMI medium (5% heat
inactivated fetal bovine serum (FBS), 2 mM L-glutamine and 100 U
of penicillin–streptomycin). The supernatant was harvested 144 h
later, then aliquoted, stored at 70 8C and titrated by plaque
formation on BHK-21 cells.
2.3. Analysis of the antibody response
The anti-DEN IgG antibodies stimulated by immunization were
monitored by an ampliﬁed sandwich ELISA system as previously
described.18 Absorbancewas read at 492 nm in amicroplate reader
(SensIdent Scan; Merck, Germany). Titers were deﬁned as the
dilution of serum giving twice the absorbance value of the negative
control serum.
The functionality of the antibodies was measured by neutra-
lization of DEN-2 infectivity by a PRNT on BHK-21 cell culture as
previously described.25
2.4. Virus detection by ELISA
Flat-bottomed 96-well plates (Costar, USA) were coated with
anti-DEN human IgG (5 mg/ml) for 2 h at 37 8C. Plates were thenblocked with 2% bovine serum albumin (BSA) and incubated for
1 h at 37 8C. After two washes with phosphate-buffered saline/
Tween-20 (PBS-T), culture supernatant was added in triplicate to
each well and plates were incubated for 2 h at 37 8C. Three
additional washes were performed and then polyclonal hyper-
immune mouse ascitic ﬂuid, diluted 1:2000 in PBS-T with 1%
normal mouse brain antigen was added to the plates. After 1 h of
incubation at 37 8C, plates were washed again three times and
then anti-mouse IgG–peroxidase conjugate (Sigma, USA) was
added. Plates were incubated for 1 h at 37 8C, washed three times,
and 0.04% substrate solution (O-phenylenediamine in buffer 2%
Na2HPO4, 1% citric acid, and 30% H2O2, pH 5.0) was added. The
reaction was stopped 30 min later by the addition of 12.5% H2SO4
and the absorbance was read at 492 nm in a microplate reader
(SensIdent Scan). A value of absorbance of two-fold the
absorbance of the supernatant from an uninfected culture was
considered as positive.
2.5. Virus detection by ﬂow cytometry
Vero cells were removed from the ﬂask using a cell scraper and
distributed into triplicate tubes at 106 cells per tube. The cells
were ﬁxed using 3% formaldehyde in phosphate-buffered saline
(PBS) for 15 min, and 0.1% Triton X-100 was employed to
permeabilize ﬁxed cells. After washing with PBS, the cells were
incubated with the monoclonal antibody 4G2 for 30 min at 4 8C.
Cells were then washed and incubated with ﬂuorescein iso-
thiocyanate (FITC)-labeled anti-mouse IgG for 30 min at 4 8C.
After incubation cells were washed again, suspended in PBS and
then analyzed using a FACScan ﬂow cytometer PASIII (Partec
GmbH, Mu¨nster, Germany). Non-infected cells were used as
negative control and cells infected with DEN-2 virus (strain
SB8553) at 0.001 multiplicity of infection were used as positive
control. A value of three-fold the value of non-infected cells was
considered as positive.
2.6. Measurement of cell-mediated immunity
Blood was obtained by venepuncture at days 0 and 60 after the
dose with infective virus DEN-2 and at days 0 and 30 after the dose
with PD5–CPS-A formulation. The peripheral blood mononuclear
cells (PBMC) were isolated over Ficoll-PaqueTM Plus (Amersham
Biosciences AB, Uppsala, Sweden) density gradient centrifugation.
Cells were washed twice with PBS–2% FBS (PAA Laboratories,
Canada) and resuspended at 2  106 cells/ml in RPMI-1640
medium (Sigma Aldrich, Ayrshire, UK) supplemented with 100
U/ml penicillin, 100 mg/ml streptomycin (Gibco), 2 mM glutamine
(Glutamax, Gibco), 5  105 M 2-mercaptoethanol (Sigma St.
Louis, MO) and 5% FBS. Finally 2  105 cells/well were cultured in
96-well round bottom plates with the antigens (3 log10 plaque-
forming units (PFU) of DEN-2 antigen or mock preparation).
Concanavalin A (ConA; Sigma St. Louis, MO) was used as a positive
control. In all the experiments three wells were plated for each
antigen. After four days of culture, culture supernatants were
collected and stored a 20 8C.
The culture supernatants previously stimulated with each
antigen were analyzed in duplicate for interferon-g (INF-g)
concentration by ELISA using monoclonal antibody pairs (Mabtech
INF-g;Mabtech, Sweden). The ELISA protocol recommended by the
manufacturer was used with slight modiﬁcations. The lower limit
of detection of cytokine in this assay was 4 pg/ml.
2.7. Study design 1
The recombinant protein preparation, animal immunization
and viral challenge have been described in detail elsewhere.18
Figure 1. Timeline diagram of the heterologous prime-boost strategies combining PD5–CPS-A and the infective DEN-2 virus. Numbers in bold indicate days of immunizations
with recombinant protein (P) or placebo formulations (P) and infective DEN-2-virus. Smaller typeface numbers indicate bleeding days.
Table 1
Neutralizing antibody response, measured by plaque reduction neutralization test
(PRNT), in immunized and subsequently challenged monkeys of study 1
Post-challenge neutralizing titersa on day:
Monkeys 0 (challenge) 30 60 255 420
PBS I <10 <10 44 NT NT
II <10 <10 38.5 NT NT
III <10 <10 29.3 NT NT
GMT <10 <10 36.8 NT NT
PD5–CPS-A I 73.3 300 117.8 130 100
II 78.3 440 103.9 81.5 43.2
GMT 75.8 363.3 110.6 102.9 65.7
DEN-2 I 133.3 323 150 NT NT
II 40.5 500 150 NT NT
III 41.1 138 114 NT NT
GMT 60.5 281.4 136.9 NT NT
GMT, geometric mean titer; NT, not tested.
The results are given as antibody titers.
a Neutralizing antibody titers are the highest serum dilution that resulted in a
50% reduction in the number of plaques produced by DEN-2 virus (strain SB8553).
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286–426, of E glycoprotein fromDEN-2 strain Jamaica, fused to the
C-terminus of the carrier protein P64k. PD5 was obtained under
Good Manufacturing Practices (GMP) conditions (Lot 21061) and
was employed for the present study. The serogroup A capsular
polysaccharide (CPS-A) from N. meningitidis and aluminum
hydroxide were used as adjuvant.
Animals were divided into three groups. Two animals of the
ﬁrst group were subcutaneously injected with 100 mg of the
recombinant protein PD5 combined with 5 mg of CPS-A. As
control groups, three animals were inoculated with a single dose
of 5 log10 PFU of DEN-2 strain SB8553 and a further three
animals received PBS. Doses were administered at days 0, 30, 90,
and 150 for the PBS and PD5–CPS-A groups, using aluminum
hydroxide at a ﬁnal concentration of 1.44 mg/ml. Animals of the
DEN-2 group were inoculated on day 105. Each immunization
was given in a ﬁnal volume of 0.5 ml, injected into four different
sites on the back. The challenge with 5 log10 PFU of DEN-2
was carried out 45 days after the last dose for groups PBS and
PD5–CPS-A and for the DEN-2 group was carried out at 3 months
after the single dose. For serological studies, three additional
blood samples were taken at days 10, 20, 30, and 60 after
challenge. Animals from the PD5–CPS-A group were additionally
bled at days 225 and 420 post-challenge. Figure 1 shows the
timeline diagram of the immunization schedule and bleeding
days.
2.8. Study design 2
Four monkeys were subcutaneously inoculated in the upper
arms with 4 log10 PFU infective virus DEN-2 strain SB8553.
Blood was collected daily for 10 days to detect viremia. Sera
from clotted blood were stored at –70 8C until viremia was
analyzed.
The presence of virus in the sera was determined by inoculating
0.15 ml of undiluted serum onto Vero cells grown in 25 cm2 ﬂasks.
After 1 h of incubation at 37 8C, an additional 3 ml of fresh
supplemented RPMImediumwere added to the ﬂasks and cultures
were incubated for 6 days. The culture supernatantswere collected
and assayed for the presence of virus by ELISA, while cells were
harvested and evaluated by ﬂow cytometry.
Five months after the viral inoculation, the four monkeys
were subcutaneously injected with 300 mg of the recombinant
protein PD5 combined with 20 mg of CPS-A using aluminum
hydroxide at a ﬁnal concentration of 1.44 mg/ml (300+20). Each
immunization was given in a ﬁnal volume of 0.5 ml, injected into
four different sites on the back. For serological studies, additional
blood samples were taken at days 30, 60, 90, 120, and 180 after
immunization.3. Results
3.1. Study 1
3.1.1. Humoral immune response of dengue-2 infected monkeys
previously sensitized with the PD5–CPS-A formulation
Animals that were immunized with four doses of the
recombinant protein PD5 formulated with CPS-A from N.
meningitidis, were then challenged with one dose of the infective
DEN-2 virus. As positive control, one group of monkeys received a
single dose of infective virus, whereas the negative control group
received only PBS. The humoral immune response characterized
after immunizations with the recombinant formulation, as well as
the protective capacity upon virus challenge, have been described
in detail in a previous report.18 In the present study, the humoral
immune response post-challenge, measured by antiviral and
neutralizing antibodies, was determined, as shown in Figure 2
and Table 1.
As shown, high levels of total antiviral and neutralizing
antibodies were elicited after DEN-2 challenge in the group
primed with the PD5–CPS-A formulation, similarly to those
developed in the group that received a single dose of DEN-2 virus.
In the case of the negative control group (immunized with PBS and
then challenged with the infective virus), the levels of antibodies
were lower than those elicited in the rest of the groups. The
similarity of antibody titers between the DEN-2 and PD5–CPS-A
groups was observed for all the points at which the determinations
were performed (at days 10, 20, 30 and 60 post-challenge), hence
we only selected the PD5–CPS-A group to study the duration of the
Figure 2. Kinetics of IgG antibodies against DEN-2 virus after challenge in vaccinated monkeys of study 1 that received phosphate-buffered saline (PBS) or one dose of DEN-2
virus or PD5–CPS-A formulation. On day 0, animals were infected with DEN-2 virus (black arrow).
Figure 3. Kinetics of IgG antibodies against DEN-2 virus in study 2. Animals were
infectedwith DEN-2 virus (black arrow) and 5months later received one dose of the
PD5–CPS-A formulation (white arrow).
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Table 1, total antiviral and neutralizing antibodies were still
detected at day 420, indicating the durability of the humoral
immune response induced.
3.2. Study 2
Basedonstudy1 inwhich thepriming capacityof the PD5–CPS-A
formulation was conﬁrmed, a second monkey study was designed.
In this case, the main goal was to prove the boosting capacity of the
recombinant protein formulation after one inoculation with
infective virus; therefore, a higher dose of the recombinant
formulation was selected (300+20). The schedule included four
animals that were infected with a single dose of infective DEN-2
virus and 5 months later received the PD5–CPS-A formulation.
3.2.1. Humoral immune response of dengue-2 infected greenmonkeys
subsequently boosted with the PD5–CPS-A formulation
The four monkeys selected for the study were infected with 4
log10 PFU of the DEN-2 viral strain SB8553. Five months later,
monkeys received one dose of the PD5–CPS-A formulation
(300+20), and antiviral and neutralizing antibodies elicited during
the immunization were determined, as shown in Figure 3 and
Table 2. Antiviral and neutralizing antibodies were developed after
the infection with DEN-2 virus, reaching maximum values at days
30 and 60. Following this, when the recombinant protein
formulation was administered, a peak of antibody response was
elicited at day 180 (measured by both techniques), reaching titers
higher than those elicited at 60 days after the single infective dose.
The boosting effect at day 180was clearly evidenced since antiviral
titers rose from 2200 (at day 150) to 38 400 (at day 180), whereasthe neutralizing titers increased from 35.1 (at day 150) to 353.5 (at
day 180). As shown in Figure 3 and Table 2, total antiviral and
neutralizing antibodies were also detected at day 330, indicating
the durability of the humoral immune response induced.
3.2.2. Induction of cell-mediated immune response
To characterize the cellular immune response, IFN-g secretion
wasmeasured usingmonkey PBMC in vitro stimulatedwith DEN-2
virus. Speciﬁcally for dengue virus, this cytokine has been
suggested to play an antiviral role and to be related to the CD8
cytotoxic activity.26,27 As shown in Figure 4, a high concentration
of IFN-g was detected at day 60, after a single dose of infective
virus. In turn, at day 150, levels decreased at values of 117.5  30.9
Table 2
Neutralizing antibody response in immunized monkeys of study 2, measured by plaque reduction neutralization test (PRNT)
Post-challenge neutralizing titersa on day:
Monkeys 0 (infection) 60 150 (boost) 180 270 330
DEN-2/PD5–CPS-A I <10 64.7 30 282 132.4 113.5
II <10 36.1 39 409.6 105.3 204.8
III <10 67.2 24 270.4 94 82.4
IV <10 86.3 54.4 500 201.4 125
GMT <10 60.7 35.1 353.5 127.5 124.4
GMT, geometric mean titer.
The results are given as antibody titers.
a Neutralizing antibody titers are the highest serum dilution that resulted in a 50% reduction in the number of plaques produced by DEN-2 virus (strain SB8553).
Figure 4. Concentration of IFN-g in culture supernatants of dengue-stimulated
PBMC from monkeys. Culture supernatants of mock or DEN-2 antigen-stimulated
PBMC were tested by ELISA. Data represent mean  SEM from two different
experiments.
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after protein administration.
4. Discussion
The heterologous prime-boost strategy is a prominent approach
that is being widely used in several immunization schedules for
inducing a functional immune response against different patho-
gens.28 Speciﬁcally, in the case of dengue vaccine studies, Simmons
et al.,15 Chen et al.,29 Brandler et al.,30 and Khanam et al.31 have
reported prime-boost experiments based on combinations of
different vaccine candidates. In the study by Simmons et al.15 no
evidence of suitable combinations was obtained, whereas Khanam
et al. reported a functional immune response when a recombinant
adenovirus carrying domain III of the dengue E protein was
combined with a DNA formulation containing the same con-
struct.31 Additionally, a similar approach employing a recombinant
Venezuelan equine encephalitis virus replicon, combined with a
DNA construct carrying the dengue structural genes was evaluated
in monkeys with successful results.29 Nevertheless, strategies
directed to combining non-replicative candidates with attenuated
dengue virus remain unexplored. Particularly, the most advanced
candidates against dengue are attenuated viral strains, which
require two or three dose schedules 6 months apart in humans to
induce an appropriate balanced immune response against the four
dengue serotypes.5,7 Therefore, any strategy that can reduce the
number of inoculations with the attenuated strains, by replacing
them with safe formulations, should be considered.
In the presentworkwe assumed the replicative virus as amodel
of attenuated virus to prove the concept of a prime-boost strategy
in combination with a subunit vaccine candidate. Positive control
animals received either one or two viral doses, since experiments
in humans require at last two administrations of live-attenuated
vaccines.5,7In the ﬁrst study, the administration of four doses of the PD5–
CPS-A formulation sensitized the immune system of inoculated
animals to subsequent inoculation with a single dose of infective
virus. This behavior was consistent with the results of partial
protection induced by that formulation in monkeys.18 This reﬂects
the importance of having a suitable adjuvant in the ﬁnal
formulation in order to achieve an appropriate priming effect.
On the other hand, levels of neutralizing antibodies raised under
the PD5–CPS-A prime/DEN-2 boost regime were higher than those
generated after one viral dose, and, in turn, similar to those reached
upon two viral doses. This behavior, detected until day 60 upon
boost immunizations, supports the suitability of the heterologous
prime/boost strategy as an alternative to the homologous prime/
boost immunizations using live viruses as immunogens. In
addition, peak levels of neutralizing antibodies reached after the
viral boost in the PD5–CPS-A group were higher at day 30
(geometric mean titer (GMT) 363.3) than those detected 15 days
upon the last dose of the recombinant protein formulation (GMT
234.5).18 These results, together with the proved length of the
neutralizing antibody response for more than one year upon viral
boost, demonstrates the superiority of the heterologous prime/
boost strategy with respect to the vaccination just using the
recombinant protein formulation.
The potential priming capacity of the chimeric protein PD5 has
been previously reported by our group in a vaccination schedule
with infective virus32 where authors studied possible surrogates of
protection post-challenge. In that work, the formulations con-
tained Freund’s adjuvant, which is not suitable for human use.
Moreover, in the present study PD5 was obtained under GMP
conditions, free of pyrogens and more than 95% of purity.
Three additional studies have described strong anamnestic
response after challenge in monkeys immunized with three
different formulations containing the recombinant E protein
from dengue.10,12,13 One of these studies, reported by our group,
characterized the E protein obtained at low yields in yeast Pichia
pastoris, but was eventually found not suitable for developing a
vaccine candidate.12 The same disadvantage was attributed to
the E protein obtained in a baculovirus system,10 whereas a
construct expressed in a Drosophila cell line by Hawaii Biotech,
was found suitable for developing a vaccine candidate and was
also able to sensitize the immune system of monkeys to virus
inoculation.13 Nevertheless, in the latter report, the durability of
the humoral immune response post-challenge was not deter-
mined. All these results coincide with our present ﬁndings – that
it is possible to sensitize the immune system with the
administration of a recombinant construct based on the E
protein of dengue virus.
There have been other studies in monkeys evaluating non-
replicative vaccine candidates such as DNA constructs and
inactivated virus. However, their capacity to prime an immune
response against infective virus inoculation was not characterized
in detail.13,15,33
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been demonstrated by other groups when the anamnestic
response post-challenge was determined, its capacity to boost
the immune response elicited after virus infection in monkeys
remains unexplored. Recently, only one study in mice reported the
boosting capacity of a recombinant construct based on domain III
of the E protein combining it with a recombinant measles virus.30
In study 2 of the present work, the administration of protein
PD5 adjuvanted in aluminum hydroxide and CPS-A was able to
recall the humoral and cellular immune response previously
primed by the administration of a single dose of infective DEN-2
virus. The interval of 5 months between virus infection and the
recombinant administration was selected based on the same
interval between the ﬁrst dose of the protein and the replicative
boost in study 1. Nevertheless, it was not possible to deﬁne which
regimen was the best one (PD5–CPS-A/DEN-2 or DEN-2/PD5–CPS-
A) due to the different viral doses used in the two studies
described.
This work suggests that the combination of the chimeric
proteins P64k-DEN and attenuated virus vaccine candidates may
result in condensed immunization schedules for humans, thus
reducing the number of doses with attenuated virus and time
spacing. On the other hand, the suitable combination using
proteins without the viral interference phenomenon can help
induce a balanced response against the fours serotypes. In
addition, priming with recombinant proteins has the potential
advantage of reducing the reactogenicity of attenuated candidates,
since the immune response induced by one dose of the protein can
reduce the viral load of the vaccine strain without affecting the
boosting capacity of the virus.
Regarding the proved immunogenicity in mice and monkeys of
the chimeric proteins P64k–domain III,22,23,14,16,17,18 its prime-
boost capacity combined with the infective virus in monkeys, the
feasible scalable puriﬁcation process already established under
GMP conditions, and its potential safety in humans, we recom-
mend the prime-boost strategy using the formulation PD5–CPS-A
and the homologous attenuated viral strains. Further experiments
to prove the hypothesis are being conducted.
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